<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527682</url>
  </required_header>
  <id_info>
    <org_study_id>2008-004763-19</org_study_id>
    <nct_id>NCT01527682</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma</brief_title>
  <official_title>Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor for the Treatment of Pediatric Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

      The study will assess the ocular hypotensive effect of latanoprost and dorzolamide in a
      selected sample of patients affected by primary Pediatric Glaucoma (PG), refractory to
      surgical procedures. Safety will be assessed, too.In the first version of the protocol 96
      eyes were forecasted to complete the enrolment. The protocol was then amended and now to
      complete the study 68 eyes should be included. This number of eyes could be achieved by
      recruiting from 34 to 68 patients due to not in all patients both eyes should be eligible for
      the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      Single arm, prospective, experimental study. Due to ethical reasons and in order to adhere as
      much as possible to current clinical practice, the presence of a control arm is not planned.
      Due to the non-comparative nature of the study, no blinding of treatment is planned.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Eyes With Response</measure>
    <time_frame>3 years</time_frame>
    <description>defined as those eyes in which the decrease of intraocular pressure (IOP) of at least 20% with respect to baseline assessment will be achieved and maintained during the 3-year period of study duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>3 years</time_frame>
    <description>calculated as the time from the date of baseline visit to the date in which the medical treatment will be stopped, since IOP control will be considered not satisfactory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With an Adverse Event (AE)</measure>
    <time_frame>3 years</time_frame>
    <description>The occurrence of the following events will be monitored: growth of the eyelashes (hypertrichosis), changes iris colour, corneal epitheliopathy, allergic conjunctivitis, increase of central corneal thickness, non-serious and serious adverse event occurrence.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Childhood Glaucoma</condition>
  <arm_group>
    <arm_group_label>Latanoprost, Dorzolamide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost, Dorzolamide</intervention_name>
    <description>Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost</description>
    <arm_group_label>Latanoprost, Dorzolamide</arm_group_label>
    <other_name>- Latanoprost, a prostaglandin analogue</other_name>
    <other_name>- Dorzolamide, a potent inhibitor of carbonic anhydrase II</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of either sexes, aged 0-12 years

          -  Diagnosis of mono- or bilateral primary congenital glaucoma

          -  IOP greater than or equal to 22 mmHg and lower than 27 mmHg

          -  Only one previous ocular hypotensive surgical procedure for treatment of glaucoma
             among the following: goniotomy, trabeculotomy, trabeculotomy with adjunct of mitomycin
             C) (only for medical treatment at least one month before)

          -  Parent informed consent to data processing (at registration)

          -  Parent informed consent before any study procedure

        Exclusion Criteria:

          -  Secondary glaucoma (Sturge-Weber syndrome, type I neurofibromatosis, retinoblastoma,
             steroid-induced glaucoma, etc.)

          -  Presence of concomitant abnormalities of the anterior segment of the eye (cataract,
             iridocorneal dysgenesia, congenital uveal ectropion uvea, etc.)

          -  Previous treatment with the study drugs

          -  Presence of concomitant systemic diseases (asthma, hypertension, cardiac disease,
             renal failure, etc.) that needs treatment with drugs, that could influence IOP
             (steroids, beta-blockers, angiotensin-converting-enzyme inhibitor -inhibitors
             diuretics, etc.)

          -  Abnormalities of the cornea that could influence IOP readings (marked cornea edema)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano Quaranta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† di Brescia, Spedali Civili di Brescia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria &quot; Policlinico Vittorio Emanuele&quot; P.O. Rodolico</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Uva MG, Avitabile T, Reibaldi M, Bucolo C, Drago F, Quaranta L, Lionetti E, Longo A. Long-term efficacy of latanoprost in primary congenital glaucoma. Eye (Lond). 2014 Jan;28(1):53-7. doi: 10.1038/eye.2013.232. Epub 2013 Oct 25.</citation>
    <PMID>24158022</PMID>
  </reference>
  <results_reference>
    <citation>Quaranta L, Biagioli E, Galli F, Poli D, Rulli E, Riva I, Hollander L, Katsanos A, Longo A, Uva MG, Torri V, Weinreb RN. Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics. Adv Ther. 2016 Aug;33(8):1305-15. doi: 10.1007/s12325-016-0358-x. Epub 2016 Jun 16.</citation>
    <PMID>27312975</PMID>
  </results_reference>
  <results_reference>
    <citation>Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, Katsanos A, Longo A, Uva MG, Torri V, Weinreb RN. The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results. J Glaucoma. 2017 Nov;26(11):987-994. doi: 10.1097/IJG.0000000000000773. Erratum in: J Glaucoma. 2018 May;27(5):e105.</citation>
    <PMID>28957960</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <results_first_submitted>May 17, 2018</results_first_submitted>
  <results_first_submitted_qc>September 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2019</results_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Luciano Quaranta MD</investigator_full_name>
    <investigator_title>Associate Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Intraocular pressure</keyword>
  <keyword>Latanoprost</keyword>
  <keyword>Dorzolamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive Primary Congenital Glaucoma not sufficiently responder to a single surgical procedure</recruitment_details>
      <pre_assignment_details>Patients affected with Primary congenital glaucoma will be recruited if after a single surgical procedure Intraocular pressure will be ranging from 22 and 27 mm Hg</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Latanoprost, Dorzolamide</title>
          <description>According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
Latanoprost, Dorzolamide: - Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
- Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Latanoprost, Dorzolamide</title>
          <description>According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
Latanoprost, Dorzolamide: - Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
- Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Response</title>
        <description>defined as those eyes in which the decrease of intraocular pressure (IOP) of at least 20% with respect to baseline assessment will be achieved and maintained during the 3-year period of study duration</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Dorzolamide</title>
            <description>According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
Latanoprost, Dorzolamide: - Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
- Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Response</title>
          <description>defined as those eyes in which the decrease of intraocular pressure (IOP) of at least 20% with respect to baseline assessment will be achieved and maintained during the 3-year period of study duration</description>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Proportion</param_type>
            <param_value>76.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64.1</ci_lower_limit>
            <ci_upper_limit>89.4</ci_upper_limit>
            <other_analysis_desc>The statistical analysis was performed according to study design. Using a Fleming single stage design (A‚ÄôHern approach) setting the probability of erroneously concluding that the responders rate is greater than 35% at 5% (one-sided alpha=0.05) and the probability of correctly concluding that the responders rate is at least 50% at 80% (beta error = 0.20), the minimum number of responder eyes was set at 31 out of 68, since this result is associated with a lower limit of the 90% exact confidence interval of 35.2%.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF)</title>
        <description>calculated as the time from the date of baseline visit to the date in which the medical treatment will be stopped, since IOP control will be considered not satisfactory</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Dorzolamide</title>
            <description>According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
Latanoprost, Dorzolamide: - Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
- Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF)</title>
          <description>calculated as the time from the date of baseline visit to the date in which the medical treatment will be stopped, since IOP control will be considered not satisfactory</description>
          <units>eyes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With an Adverse Event (AE)</title>
        <description>The occurrence of the following events will be monitored: growth of the eyelashes (hypertrichosis), changes iris colour, corneal epitheliopathy, allergic conjunctivitis, increase of central corneal thickness, non-serious and serious adverse event occurrence.</description>
        <time_frame>3 years</time_frame>
        <population>Eyes affected by Primary congenital glaucoma not sufficiently responder to a single surgical procedure</population>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Dorzolamide</title>
            <description>According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
Latanoprost, Dorzolamide: - Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
- Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With an Adverse Event (AE)</title>
          <description>The occurrence of the following events will be monitored: growth of the eyelashes (hypertrichosis), changes iris colour, corneal epitheliopathy, allergic conjunctivitis, increase of central corneal thickness, non-serious and serious adverse event occurrence.</description>
          <population>Eyes affected by Primary congenital glaucoma not sufficiently responder to a single surgical procedure</population>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Latanoprost / Dorzolamide</title>
          <description>According to IOP assessment, the eye will receive Latanoprost, Dorzolamide or both.
Latanoprost, Dorzolamide: - Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
- Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Iris color modification</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Corneal epitheliopathy</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Allergic conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Eyelid skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Luciano Quaranta</name_or_title>
      <organization>ASST Spedali Civili di Brescia</organization>
      <phone>+39 030 3995 ext 847</phone>
      <email>luciano.quaranta@unibs.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

